<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875417</url>
  </required_header>
  <id_info>
    <org_study_id>HEP001</org_study_id>
    <nct_id>NCT03875417</nct_id>
  </id_info>
  <brief_title>Multidisciplinary Management of HCC in Elderly Patients</brief_title>
  <official_title>Multidisciplinary HCC Treatment in Elderly : QoL and Survival Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Policlinico Umberto I</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Policlinico Umberto I</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate whether treating HCC recurrences in resected elderly
      patients is advantageous or not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction- Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It
      usually develops in cirrhotic liver with high recurrence rates. More than 2/3 of patients are
      elderly, often excluded from surgery and follow-up protocols. Aim of this study is to
      evaluate whether treating HCC recurrences in resected elderly patients is advantageous or
      not.

      Materials and methods- 126 patients, aged between 65 and 90 years, submitted to liver
      resection for HCC were enrolled. They were divided into three classes. Class 1 included
      patients submitted to major resections, Class 2 to minor resections and Class 3 to minor
      resections associated with thermoablation. All of them were clinically and radiologically
      followed up. Patients who developed recurrences (Group A) were referred to further treatments
      (surgery, interventional radiology or pharmacological therapy). Mortality, disease-free
      survival (DFS), overall survival (OS) and quality of life (QoL) were evaluated and compared
      with non-recurrent patients (Group B).

      Used interventional radiology means were Radiofrequency ablation (RF), microwaves ablation
      (MWA) or transcatheter arterial chemoembolization (TACE).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>follow up time 1-16 years</time_frame>
    <description>survival in months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>follow up time 1-16 years</time_frame>
    <description>survival without recurrences in months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Karnofsky performance scale</measure>
    <time_frame>follow up time 1-16 years</time_frame>
    <description>evaluation of performance status in dimensionless scale 0 - 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of Daily living</measure>
    <time_frame>follow up time 1-16 years</time_frame>
    <description>assess the ability to manage common routine activities evaluated in dimensionless scale 1-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental Activity of Daily living</measure>
    <time_frame>follow up time 1-16 years</time_frame>
    <description>assess the ability to use common instruments evaluated in dimensionless scale 1-8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Haemoglobin</measure>
    <time_frame>follow up time 1-16 years</time_frame>
    <description>evaluation of mean haemoglobin levels in g/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Albumin</measure>
    <time_frame>follow up time 1-16 years</time_frame>
    <description>evaluation of mean albumin levels in g/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale</measure>
    <time_frame>follow up time 1-16 years</time_frame>
    <description>evaluation of depression in patients in dimensionless scale 0 - 15</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">126</enrollment>
  <condition>HCC</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients who developed HCC recurrences after surgery and treated with re-resection, or microinvasive non-surgical means.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients who did not develop recurrences after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>liver resection</intervention_name>
    <description>resection of one or more HCC nodules within the liver</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermic ablation</intervention_name>
    <description>ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>RF (radiofrequency ablation) / MWA (microwaves ablation)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter arterial chemoembolization</intervention_name>
    <description>embolization of HCC nodule via drug-eluted microbeads.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patients submitted to surgery for HCC nodules resection between 2002 and 2017
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCC patient

          -  eligible for surgery

        Exclusion Criteria:

          -  non eligible for surgery at first HCC diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefania Brozzetti, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Umberto I - Sapienza universit√† di Roma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgery &quot;Pietro Valdoni&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 10, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Policlinico Umberto I</investigator_affiliation>
    <investigator_full_name>Professor Stefania Brozzetti</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>HCC in elderly</keyword>
  <keyword>recurrent HCC</keyword>
  <keyword>Liver resection</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>intervention radiology</keyword>
  <keyword>RF</keyword>
  <keyword>TACE</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

